Get the Stockscreener App
4.69
5.63%
0.25
After Hours:
4.60
-0.09
-1.92%
Grace Therapeutics Inc stock is traded at $4.69, with a volume of 911.23K.
It is up +5.63% in the last 24 hours and up +15.23% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$4.44
Open:
$4.51
24h Volume:
911.23K
Relative Volume:
4.29
Market Cap:
$72.57M
Revenue:
-
Net Income/Loss:
$-5.98M
P/E Ratio:
-13.02
EPS:
-0.3603
Net Cash Flow:
$-9.83M
1W Performance:
+5.63%
1M Performance:
+15.23%
6M Performance:
+52.27%
1Y Performance:
+83.20%
1-Day Range:
$4.4717
$4.94
1-Week Range:
$4.2601
$4.94
52-Week Range:
$1.75
$4.94
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
4.69 | 68.70M | 0 | -5.98M | -9.83M | -0.3603 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8% - MarketBeat
Analyst Upgrade: How much upside does New Fortress Energy Inc haveWeekly Investment Recap & Low Risk Entry Point Tips - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
PUGBY News & Events - Intellectia AI
If You Invested $1,000 in Grace Therapeutics, Inc (GRCE) - Stock Titan
EVSB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
EVSB PE Ratio & Valuation, Is EVSB Overvalued - Intellectia AI
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GARP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
DALN Technical Analysis & Price Forecast - Intellectia AI
WASH.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Returns Recap: Can Grace Therapeutics Inc maintain sales growth2026 Trade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why is Grace Therapeutics Inc stock going up2026 Momentum Check & AI Powered Market Entry Ideas - baoquankhu1.vn
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences - The Manila Times
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times
Why some brain bleed patients miss full doses takes center stage at 2 meetings - Stock Titan
RGNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Market Trends: Is KIMPRN a play on infrastructure spending2026 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Traumatic Brain Injury Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Neuren Pharma, NeuroVive Pharma, Stemedica Cell Techn, Grace Lab - Barchart
Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update - MarketBeat
Is Grace Therapeutics Inc. stock positioned for digital transformation2025 Trade Ideas & AI Forecasted Entry and Exit Points - Naître et grandir
Aug Selloffs: What is the cash position of Willis Lease Finance Corporation2025 Short Interest & Technical Confirmation Alerts - baoquankhu1.vn
Aug Patterns: Will Haoxin Holdings Limited stock outperform Nasdaq indexTrend Reversal & Weekly Watchlist for Hot Stocks - Naître et grandir
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Aug Momentum: Is now the right time to enter SAIA2025 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn
GRCE SEC FilingsGrace Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRCE: IV nimodipine shows superior efficacy and compliance over oral forms for aSAH treatment - TradingView
Institution Moves: What is Grace Therapeutics Incs valuation compared to sector2025 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
Is OXLC.G forming a breakout patternPortfolio Performance Report & Free Daily Entry Point Trade Alerts - mfd.ru
Rate Hike: Can Grace Therapeutics Inc weather a recessionProfit Target & Reliable Price Action Trade Plans - baoquankhu1.vn
ANTX PE Ratio & Valuation, Is ANTX Overvalued - Intellectia AI
PYPD PE Ratio & Valuation, Is PYPD Overvalued - Intellectia AI
GRCE Should I Buy - Intellectia AI
Buy Signal: Is MSAI forming a breakout pattern2025 Trading Volume Trends & Expert Approved Momentum Ideas - baoquankhu1.vn
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - Bitget
Grace CEO joins TD Cowen event with IV nimodipine program - Stock Titan
The 9 Best Robinhood Penny Stocks in March 2026 - The Stock Dork
Stop Loss: Does CRVS stock benefit from AI growthWeekly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
NVIDIA Corporation (NVDA) to Supply Standalone Grace CPUs in Landmark Data Center Rollout - Yahoo Finance
Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth - Sahm
ADAR1 discloses 9.9% Grace Therapeutics (GRCE) ownership in 13G/A - Stock Titan
Aug PreEarnings: Is Grace Therapeutics Inc a turnaround storyMarket Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
SAPMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can MetaVia Inc. stock outperform in a bear marketTreasury Yields & Proven Capital Preservation Methods - mfd.ru
Will Grace Therapeutics Inc. stock sustain high P E ratios2025 Technical Patterns & Daily Growth Stock Investment Tips - mfd.ru
Does Grace Therapeutics Inc. have a sustainable dividend2025 Volume Leaders & Real-Time Volume Surge Alerts - mfd.ru
Is EVGOW stock a top momentum playPortfolio Update Report & Daily Entry Point Alerts - mfd.ru
Is SFYX stock good for wealth creation2025 Price Momentum & Real-Time Volume Analysis - mfd.ru
GRCE PE Ratio & Valuation, Is GRCE Overvalued - Intellectia AI
BOL.ST Should I Buy - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):